Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 2
2004 4
2005 5
2006 1
2007 1
2008 5
2009 6
2010 1
2012 1
2014 4
2015 5
2016 6
2017 1
2018 3
2019 2
2020 7
2021 3
2022 4
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
[Diagnostic workup for polyneuropathy].
Eilers-Petri C, Oberhagemann A, Mäurer M. Eilers-Petri C, et al. Among authors: maurer m. Schmerz. 2024 Apr 19. doi: 10.1007/s00482-024-00808-y. Online ahead of print. Schmerz. 2024. PMID: 38639809 German.
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories.
Gross CC, Schulte-Mecklenbeck A, Steinberg OV, Wirth T, Lauks S, Bittner S, Schindler P, Baranzini SE, Groppa S, Bellmann-Strobl J, Bünger N, Chien C, Dawin E, Eveslage M, Fleischer V, Gonzalez-Escamilla G, Gisevius B, Haas J, Kerschensteiner M, Kirstein L, Korsukewitz C, Lohmann L, Lünemann JD, Luessi F, Meyer Zu Hörste G, Motte J, Ruck T, Ruprecht K, Schwab N, Steffen F, Meuth SG, Paul F, Wildemann B, Kümpfel T, Gold R, Hahn T, Zipp F, Klotz L, Wiendl H; German Competence Network Multiple Sclerosis (KKNMS). Gross CC, et al. Sci Transl Med. 2024 Mar 27;16(740):eade8560. doi: 10.1126/scitranslmed.ade8560. Epub 2024 Mar 27. Sci Transl Med. 2024. PMID: 38536936
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.
Krause N, Derad C, von Glasenapp B, Riemann-Lorenz K, Temmes H, van de Loo M, Friede T, Asendorf T, Heesen C; POWER@MS1 study group. Krause N, et al. Mult Scler Relat Disord. 2023 Nov;79:105043. doi: 10.1016/j.msard.2023.105043. Epub 2023 Oct 5. Mult Scler Relat Disord. 2023. PMID: 37839367 Free article. Clinical Trial.
Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage.
Appeltshauser L, Junghof H, Messinger J, Linke J, Haarmann A, Ayzenberg I, Baka P, Dorst J, Fisse AL, Grüter T, Hauschildt V, Jörk A, Leypoldt F, Mäurer M, Meinl E, Michels S, Motte J, Pitarokoili K, Stettner M, Villmann C, Weihrauch M, Welte GS, Zerr I, Heinze KG, Sommer C, Doppler K. Appeltshauser L, et al. Among authors: maurer m. Brain. 2023 May 2;146(5):1932-1949. doi: 10.1093/brain/awac418. Brain. 2023. PMID: 36346134 Free PMC article.
Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies.
Appeltshauser L, Messinger J, Starz K, Heinrich D, Brunder AM, Stengel H, Fiebig B, Ayzenberg I, Birklein F, Dresel C, Dorst J, Dvorak F, Grimm A, Joerk A, Leypoldt F, Mäurer M, Merl P, Michels S, Pitarokoili K, Rosenfeldt M, Sperfeld AD, Weihrauch M, Welte GS, Sommer C, Doppler K. Appeltshauser L, et al. Among authors: maurer m. Neurol Neuroimmunol Neuroinflamm. 2022 Mar 21;9(3):e1163. doi: 10.1212/NXI.0000000000001163. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35314491 Free PMC article.
[New master's program: multiple sclerosis management].
Voigt I, Stadelmann C, Meuth SG, Schipp B, Flachenecker P, Mäurer M, Funk RHW, Ramisch F, Niemeier J, Ziemssen T. Voigt I, et al. Among authors: maurer m. Wien Med Wochenschr. 2022 Nov;172(15-16):383-391. doi: 10.1007/s10354-021-00900-3. Epub 2022 Feb 2. Wien Med Wochenschr. 2022. PMID: 35107651 Free PMC article. German.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: maurer m. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
72 results